Pharmacological chaperoning of nAChRs: A therapeutic target for Parkinson's disease

Pharmacological Research

Volumn 83, Issue , 2014, Pages 20-29

  Srinivasan, Rahul ^a   Henderson, Brandon J ^b   Lester, Henry A ^b   Richards, Christopher I ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Institute of Technology   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chaperoning; Confocal; COPI; COPII; Dopaminergic; Endoplasmic reticulum stress; ER exit sites; FRET; Golgi; Ligand; nAChR; Neurodegeneration; Neuroprotection; Nicotine; Parkinson's disease; Pharmacological chaperone; TIRF; Tobacco; Unfolded protein response

Indexed keywords

BUNGAROTOXIN RECEPTOR; CHAPERONE; CHOLINERGIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA6; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

CELL FUNCTION; CELL MEMBRANE; CELL STRESS; CONFOCAL MICROSCOPY; CYTOARCHITECTURE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; GOLGI COMPLEX; HUMAN; LIGAND BINDING; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SECRETORY VESICLE; SMOKING CESSATION; STOICHIOMETRY; TOBACCO; TOBACCO DEPENDENCE; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TOBACCO USE DISORDER;

ANIMALS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEURONS; NEUROPROTECTIVE AGENTS; NICOTINE; PARKINSON DISEASE; RECEPTORS, NICOTINIC; TOBACCO USE DISORDER; UP-REGULATION;

EID: 84901948488     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.02.005     Document Type: Review

References (117)

1. R.A. Chanoux, and R.C. Rubenstein Molecular chaperones as targets to circumvent the cftr defect in cystic fibrosis Front Pharmacol 3 2012 137
2. Y. Wang, T.W. Loo, M.C. Bartlett, and D.M. Clarke Modulating the folding of p-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones Mol Pharmacol 71 2007 751 758 (Pubitemid 46294086)
3. Y. Wang, T.W. Loo, M.C. Bartlett, and D.M. Clarke Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants Biochem J 406 2007 257 263 (Pubitemid 47310956)
4. A.R. Sawkar, W.C. Cheng, E. Beutler, C.H. Wong, W.E. Balch, and J.W. Kelly Chemical chaperones increase the cellular activity of n370s beta-glucosidase: a therapeutic strategy for gaucher disease Proc Natl Acad Sci U S A 99 2002 15428 15433 (Pubitemid 35403951)
5. A.R. Sawkar, S.L. Adamski-Werner, W.C. Cheng, C.H. Wong, E. Beutler, and K.P. Zimmer et al. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles Chem Biol 12 2005 1235 1244 (Pubitemid 41628259)
6. B.K. Tamarappoo, and A.S. Verkman Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones J Clin Invest 101 1998 2257 2267 (Pubitemid 28244110)
7. S.M. Noorwez, V. Kuksa, Y. Imanishi, L. Zhu, S. Filipek, and K. Palczewski et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the p23h-opsin mutant associated with autosomal dominant retinitis pigmentosa J Biol Chem 278 2003 14442 14450 (Pubitemid 36799997)
8. M. Kosmaoglou, N. Schwarz, J.S. Bett, and M.E. Cheetham Molecular chaperones and photoreceptor function Prog Retin Eye Res 27 2008 434 449
9. B.A. Foster, H.A. Coffey, M.J. Morin, and F. Rastinejad Pharmacological rescue of mutant p53 conformation and function Science 286 1999 2507 2510
10. H. Razavi, S.K. Palaninathan, E.T. Powers, R.L. Wiseman, H.E. Purkey, and N.N. Mohamedmohaideen et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action Angew Chem 42 2003 2758 2761 (Pubitemid 36807218)
11. S.M. Johnson, S. Connelly, C. Fearns, E.T. Powers, and J.W. Kelly The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug J Mol Biol 421 2012 185 203
12. T. Coelho, L.F. Maia, A. Martins da Silva, M. Waddington Cruz, V. Plante-Bordeneuve, and P. Lozeron et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial Neurology 79 2012 785 792
13. T. Coelho, L.F. Maia, A.M. da Silva, M.W. Cruz, V. Plante-Bordeneuve, and O.B. Suhr et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy J Neurol 260 2013 2802 2814
14. T.K. Chaudhuri, and S. Paul Protein-misfolding diseases and chaperone-based therapeutic approaches FEBS J 273 2006 1331 1349 (Pubitemid 44029101)
15. T.W. Loo, and D.M. Clarke Chemical and pharmacological chaperones as new therapeutic agents Expert Rev Mol Med 9 2007 1 18 (Pubitemid 47398645)
16. R.D. Schwartz, and K.J. Kellar Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo Science 220 1983 214 216 (Pubitemid 13115272)
17. M.J. Marks, J.B. Burch, and A.C. Collins Effects of chronic nicotine infusion on tolerance development and nicotinic receptors J Pharmacol Exp Ther 226 1983 817 825 (Pubitemid 13007732)
18. M.J. Marks, J.A. Stitzel, and A.C. Collins Time course study of the effects of chronic nicotine infusion on drug response and brain receptors J Pharmacol Exp Ther 235 1985 619 628 (Pubitemid 16210725)
19. H.A. Lester, C. Xiao, R. Srinivasan, C.D. Son, J. Miwa, and R. Pantoja et al. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery AAPS J 11 2009 167 177
20. J.M. Miwa, R. Freedman, and H.A. Lester Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses Neuron 70 2011 20 33
21. 3H]nicotine binding sites in human brain J Neurochem 50 1988 1243 1247
22. 125i]-α-bungarotoxin binding in human postmortem brain J Comp Neurol 387 1997 385 398 (Pubitemid 27430337)
23. A.L. Brody, A.G. Mukhin, J. La Charite, K. Ta, J. Farahi, and C.A. Sugar et al. Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers Int J Neuropsychopharmacol 16 2013 957 966
24. J.K. Staley, S. Krishnan-Sarin, K.P. Cosgrove, E. Krantzler, E. Frohlich, and E. Perry et al. Human tobacco smokers in early abstinence have higher levels of β2* nicotinic acetylcholine receptors than nonsmokers J Neurosci 26 2006 8707 8714 (Pubitemid 44319406)
25. M. Mamede, K. Ishizu, M. Ueda, T. Mukai, Y. Iida, and H. Kawashima et al. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5ia SPECT study J Nucl Med 48 2007 1829 1835 (Pubitemid 350099329)
26. U. Wullner, D. Gundisch, H. Herzog, M. Minnerop, A. Joe, and M. Warnecke et al. Smoking upregulates α4β2* nicotinic acetylcholine receptors in the human brain Neurosci Lett 430 2008 34 37
27. K.P. Cosgrove, J. Batis, F. Bois, P.K. Maciejewski, I. Esterlis, and T. Kloczynski et al. Beta2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking Arch Gen Psychiatry 66 2009 666 676
28. D.C. Perry, M.I. Davila-Garcia, C.A. Stockmeier, and K.J. Kellar Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies J Pharmacol Exp Ther 289 1999 1545 1552 (Pubitemid 29246689)
29. R. Nashmi, C. Xiao, P. Deshpande, S. McKinney, S.R. Grady, and P. Whiteaker et al. Chronic nicotine cell specifically upregulates functional α4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path J Neurosci 27 2007 8202 8218 (Pubitemid 47219619)
30. B.J. Henderson, R. Srinivasan, W.A. Nichols, C.N. Dilworth, D.F. Gutierrez, and E.D.W. Mackey et al. Nicotine exploits a COPI-mediated process for chaperone-mediate up-regulation of its receptors J Gen Physiol 143 1 2014 51 66
31. R. Srinivasan, R. Pantoja, F.J. Moss, E.D. Mackey, C.D. Son, and J. Miwa et al. Nicotine up-regulates α4β2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning J Gen Physiol 137 2011 59 79
32. C.I. Richards, R. Srinivasan, C. Xiao, E.D. Mackey, J.M. Miwa, and H.A. Lester Trafficking of α4* nicotinic receptors revealed by superecliptic phluorin: effects of a β4 amyotrophic lateral sclerosis-associated mutation and chronic exposure to nicotine J Biol Chem 286 2011 31241 31249
33. M.J. Marks, J.R. Pauly, S.D. Gross, E.S. Deneris, I. Hermans-Borgmeyer, and S.F. Heinemann et al. Nicotine binding and nicotinic receptor subunit rna after chronic nicotine treatment J Neurosci 12 1992 2765 2784
34. X. Peng, V. Gerzanich, R. Anand, P.J. Whiting, and J. Lindstrom Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover Mol Pharmacol 46 1994 523 530 (Pubitemid 24296687)
35. C.P. Fenster, T.L. Whitworth, E.B. Sheffield, M.W. Quick, and R.A. Lester Upregulation of surface a4b2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine J Neurosci 19 1999 4804 4814 (Pubitemid 29270117)
36. J. Sallette, S. Pons, A. Devillers-Thiery, M. Soudant, L. Prado de Carvalho, and J.P. Changeux Nicotine upregulates its own receptors through enhanced intracellular maturation Neuron 46 2005 595 607
37. Y.F. Vallejo, B. Buisson, D. Bertrand, and W.N. Green Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism J Neurosci 25 2005 5563 5572 (Pubitemid 40800648)
38. A. Kuryatov, J. Luo, J. Cooper, and J. Lindstrom Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors Mol Pharmacol 68 2005 1839 1851 (Pubitemid 41654365)
39. R. Srinivasan, C.I. Richards, C. Xiao, D. Rhee, R. Pantoja, and D.A. Dougherty et al. Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response Mol Pharmacol 81 2012 759 769
40. N.L. Benowitz, H. Porchet, and P. Jacob 3rd Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations Prog Brain Res 79 1989 279 287 (Pubitemid 20047991)
41. J. Hukkanen, P. Jacob 3rd., and N.L. Benowitz Metabolism and disposition kinetics of nicotine Pharmacol Rev 57 2005 79 115 (Pubitemid 40283970)
42. S.G. Matta, D.J. Balfour, N.L. Benowitz, R.T. Boyd, J.J. Buccafusco, and A.R. Caggiula et al. Guidelines on nicotine dose selection for in vivo research Psychopharmacology (Berl) 190 2007 269 319 (Pubitemid 46156883)
43. B.A. Pollok, and R. Heim Using gfp in fret-based applications Trends Cell Biol 9 1999 57 60 (Pubitemid 29151793)
44. R. Srinivasan, C.I. Richards, C. Dilworth, F.J. Moss, D.A. Dougherty, and H.A. Lester Forster resonance energy transfer (fret) correlates of altered subunit stoichiometry in cys-loop receptors, exemplified by nicotinic α4β2 Int J Mol Sci 13 2012 10022 10040
45. C. Xiao, R. Srinivasan, R.M. Drenan, E.D. Mackey, J.M. McIntosh, and H.A. Lester Characterizing functional α6β2 nicotinic acetylcholine receptors in vitro: mutant beta2 subunits improve membrane expression, and fluorescent proteins reveal responsive cells Biochem Pharmacol 82 2011 852 861
46. F. Mazzo, F. Pistillo, G. Grazioso, F. Clementi, N. Borgese, and C. Gotti et al. Nicotine-modulated subunit stoichiometry affects stability and trafficking of α3β4 nicotinic receptor J Neurosci 33 2013 12316 12328
47. W.E. Balch, B.S. Glick, and J.E. Rothman Sequential intermediates in the pathway of intercompartmental transport in a cell-free system Cell 39 1984 525 536 (Pubitemid 15198591)
48. J.E. Rothman, and F.T. Wieland Protein sorting by transport vesicles Science 272 1996 227 234
49. J.E. Rothman The future of Golgi research Mol Biol Cell 21 2010 3776 3780
50. F. Letourneur, E.C. Gaynor, S. Hennecke, C. Demolliere, R. Duden, and S.D. Emr et al. Coatomer is essential for retrieval of dilysine-tagged proteins to the endoplasmic reticulum Cell 79 1994 1199 1207
51. L. Orci, M. Stamnes, M. Ravazzola, M. Amherdt, A. Perrelet, and T.H. Sollner et al. Bidirectional transport by distinct populations of copi-coated vesicles Cell 90 1997 335 349 (Pubitemid 27329718)
52. P.A. Pellett, F. Dietrich, J. Bewersdorf, J.E. Rothman, and G. Lavieu Inter-Golgi transport mediated by copi-containing vesicles carrying small cargoes eLife 2 2013 e01296
53. K.N. Fish Total internal reflection fluorescence (TIRF) microscopy Curr Protoc Cytom 2009 Chapter 12:Unit12 18
54. C.I. Richards, K. Luong, R. Srinivasan, S.W. Turner, D.A. Dougherty, and J. Korlach et al. Live-cell imaging of single receptor composition using zero-mode waveguide nanostructures Nano Lett 12 2012 3690 3694
55. C. Gotti, M. Moretti, A. Gaimarri, A. Zanardi, F. Clementi, and M. Zoli Heterogeneity and complexity of native brain nicotinic receptors Biochem Pharmacol 74 2007 1102 1111 (Pubitemid 47432651)
56. C. Gotti, M. Zoli, and F. Clementi Brain nicotinic acetylcholine receptors: native subtypes and their relevance Trends Pharmacol Sci 27 2006 482 491 (Pubitemid 44251225)
57. H.N. Nguyen, B.A. Rasmussen, and D.C. Perry Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography J Pharmacol Exp Ther 307 2003 1090 1097 (Pubitemid 37494228)
58. X. Peng, V. Gerzanich, R. Anand, F. Wang, and J. Lindstrom Chronic nicotine treatment up-regulates α3 and α7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y Mol Pharmacol 51 1997 776 784 (Pubitemid 27224682)
59. S. Nuutinen, E. Ekokoski, E. Lahdensuo, and R.K. Tuominen Nicotine-induced upregulation of human neuronal nicotinic α7-receptors is potentiated by modulation of camp and pkc in SH-EP1-Hα7 cells Eur J Pharmacol 544 2006 21 30 (Pubitemid 44148574)
60. X.A. Perez, T. Bordia, J.M. McIntosh, S.R. Grady, and M. Quik Long-term nicotine treatment differentially regulates striatal α6α4β 2* and α6(nonα4)β2* nachr expression and function Mol Pharmacol 74 2008 844 853
61. H. Walsh, A.P. Govind, R. Mastro, J.C. Hoda, D. Bertrand, and Y. Vallejo et al. Upregulation of nicotinic receptors by nicotine varies with receptor subtype J Biol Chem 283 2008 6022 6032
62. P. Tumkosit, A. Kuryatov, J. Luo, and J. Lindstrom B3 subunits promote expression and nicotine-induced up-regulation of human nicotinic α6* nicotinic acetylcholine receptors expressed in transfected cell lines Mol Pharmacol 70 2006 1358 1368 (Pubitemid 44435988)
63. J. Xu, Y. Zhu, and S.F. Heinemann Identification of sequence motifs that target neuronal nicotinic receptors to dendrites and axons J Neurosci 26 2006 9780 9793 (Pubitemid 44427717)
64. S. Kracun, P.C. Harkness, A.J. Gibb, and N.S. Millar Influence of the M3-M4 intracellular domain upon nicotinic acetylcholine receptor assembly, targeting and function Br J Pharmacol 153 2008 1474 1484 (Pubitemid 351481507)
65. J.R. Pauly, M.J. Marks, S.D. Gross, and A.C. Collins An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment J Pharmacol Exp Ther 258 1991 1127 1136
66. D.C. Perry, D. Mao, A.B. Gold, J.M. McIntosh, J.C. Pezzullo, and K.J. Kellar Chronic nicotine differentially regulates α6- and β3-containing nicotinic cholinergic receptors in rat brain J Pharmacol Exp Ther 322 2007 306 315 (Pubitemid 46956379)
67. M.B. Doura, A.B. Gold, A.B. Keller, and D.C. Perry Adult and periadolescent rats differ in expression of nicotinic cholinergic receptor subtypes and in the response of these subtypes to chronic nicotine exposure Brain Res 1215 2008 40 52
68. N. Champtiaux, C. Gotti, M. Cordero-Erausquin, D.J. David, C. Przybylski, and C. Lena et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice J Neurosci 23 2003 7820 7829 (Pubitemid 37055453)
69. S.R. Grady, O. Salminen, J.M. McIntosh, M.J. Marks, and A.C. Collins Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of α4β2*-nicotinic acetylcholine receptors J Mol Neurosci 40 2010 91 95
70. D. Mao, D.C. Perry, R.P. Yasuda, B.B. Wolfe, and K.J. Kellar The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo J Neurochem 104 2008 446 456 (Pubitemid 350293883)
71. M. Moretti, M. Mugnaini, M. Tessari, M. Zoli, A. Gaimarri, and I. Manfredi et al. A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes Mol Pharmacol 78 2010 287 296
72. C.R. Wageman, M.J. Marks, and S.R. Grady Effectiveness of nicotinic agonists as desensitizers at presynaptic α4β2- and α4α5β2-nicotinic acetylcholine receptors Nicotine Tobacco Res 16 3 2013 297 305 10.1093/ntr/ntt146
73. S. Chatterjee, N. Santos, J. Holgate, C.L. Haass-Koffler, F.W. Hopf, and V. Kharazia et al. α5 subunit regulates the expression and function of α4*-containing neuronal nicotinic acetylcholine receptors in the ventral-tegmental area PLoS ONE 8 2013 e68300
74. T. Darsow, T.K. Booker, J.C. Pina-Crespo, and S.F. Heinemann Exocytic trafficking is required for nicotine-induced up-regulation of α4β2 nicotinic acetylcholine receptors J Biol Chem 280 2005 18311 18320 (Pubitemid 41389077)
75. S.E. McCallum, N. Parameswaran, T. Bordia, H. Fan, J.M. McIntosh, and M. Quik Differential regulation of mesolimbic α3*/ α6*β2 and α4*β2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys J Pharmacol Exp Ther 318 2006 381 388 (Pubitemid 43922326)
76. S.E. McCallum, N. Parameswaran, T. Bordia, H. Fan, R.F. Tyndale, and J.W. Langston et al. Increases in α4* but not α3*/ α6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment J Neurochem 96 2006 1028 1041
77. (125)I]y0-α- conotoxin mii binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine Neuroscience 137 2006 565 572 (Pubitemid 43031522)
78. A.A. Jensen, B. Frolund, T. Liljefors, and P. Krogsgaard-Larsen Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations J Med Chem 48 2005 4705 4745 (Pubitemid 41038456)
79. E.X. Albuquerque, E.F. Pereira, M. Alkondon, and S.W. Rogers Mammalian nicotinic acetylcholine receptors: from structure to function Physiol Rev 89 2009 73 120
80. D.C. Lam, L. Girard, R. Ramirez, W.S. Chau, W.S. Suen, and S. Sheridan et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers Cancer Res 67 2007 4638 4647 (Pubitemid 46910168)
81. K.C. Brown, H.E. Perry, J.K. Lau, D.V. Jones, J.F. Pulliam, and B.A. Thornhill et al. Nicotine induces the up-regulation of the α7-nicotinic receptor (α7-nAChR) in human squamous cell lung cancer cells via the sp1/gata protein pathway J Biol Chem 288 2013 33049 33059
82. M. Gopalakrishnan, E.J. Molinari, and J.P. Sullivan Regulation of human α4β2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways Mol Pharmacol 52 1997 524 534 (Pubitemid 27412979)
83. M.A. Hernan, B. Takkouche, F. Caamano-Isorna, and J.J. Gestal-Otero A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease Ann Neurol 52 2002 276 284 (Pubitemid 35001493)
84. C.M. Tanner, S.M. Goldman, D.A. Aston, R. Ottman, J. Ellenberg, and R. Mayeux et al. Smoking and parkinson's disease in twins Neurology 58 2002 581 588 (Pubitemid 34164940)
85. B. Ritz, A. Ascherio, H. Checkoway, K.S. Marder, L.M. Nelson, and W.A. Rocca et al. Pooled analysis of tobacco use and risk of parkinson disease Arch Neurol 64 2007 990 997 (Pubitemid 47047999)
86. M. Quik, and S. Wonnacott α6β2* and α4β 2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease Pharmacol Rev 63 2011 938 966
87. R. Maggio, M. Riva, F. Vaglini, F. Fornai, R. Molteni, and M. Armogida et al. Nicotine prevents experimental Parkinsonism in rodents and induces striatal increase of neurotrophic factors J Neurochem 71 1998 2439 2446 (Pubitemid 28531254)
88. G. Costa, J.A. Abin-Carriquiry, and F. Dajas Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra Brain Res 888 2001 336 342 (Pubitemid 32058803)
89. R.E. Ryan, S.A. Ross, J. Drago, and R.E. Loiacono Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice Br J Pharmacol 132 2001 1650 1656 (Pubitemid 32397956)
90. K.O. Fagerstrom, O. Pomerleau, B. Giordani, and F. Stelson Nicotine may relieve symptoms of parkinson's disease Psychopharmacology (Berl) 116 1994 117 119 (Pubitemid 24279608)
91. M.C. Kelton, H.J. Kahn, C.L. Conrath, and P.A. Newhouse The effects of nicotine on Parkinson's disease Brain Cogn 43 2000 274 282 (Pubitemid 30398690)
92. T. Mitsuoka, Y. Kaseda, H. Yamashita, T. Kohriyama, H. Kawakami, and S. Nakamura et al. Effects of nicotine chewing gum on updrs score and p300 in early-onset Parkinsonism Hiroshima J Med Sci 51 2002 33 39 (Pubitemid 34456739)
93. G. Villafane, P. Cesaro, A. Rialland, S. Baloul, S. Azimi, and C. Bourdet et al. Chronic high dose transdermal nicotine in parkinson's disease: an open trial Eur J Neurol 14 2007 1313 1316 (Pubitemid 350135288)
94. N. Belluardo, G. Mudo, M. Blum, Q. Cheng, G. Caniglia, and P. Dell'Albani et al. The nicotinic acetylcholine receptor agonist (+/-)-epibatidine increases fgf-2 mRNA and protein levels in the rat brain Brain Res Mol Brain Res 74 1999 98 110 (Pubitemid 30038183)
95. (2+) dependent mechanism Neuropharmacology 39 2000 2799 2807
96. G. Mudo, N. Belluardo, and K. Fuxe Nicotinic receptor agonists as neuroprotective/neurotrophic drugs: progress in molecular mechanisms J Neural Transm 114 2007 135 147 (Pubitemid 46018681)
97. 2+ FASEB J 25 2011 2563 2573
98. H.A. Lester, J.M. Miwa, and R. Srinivasan Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects Biol Psychiatry 72 2012 907 915
99. D. Ron, and P. Walter Signal integration in the endoplasmic reticulum unfolded protein response Nat Rev Mol Cell Biol 8 2007 519 529 (Pubitemid 46985379)
100. P. Walter, and D. Ron The unfolded protein response: from stress pathway to homeostatic regulation Science 334 2011 1081 1086
101. B.M. Gardner, D. Pincus, K. Gotthardt, C.M. Gallagher, and P. Walter Endoplasmic reticulum stress sensing in the unfolded protein response Cold Spring Harb Perspect Biol 5 2013 a013169
102. D. Lindholm, H. Wootz, and L. Korhonen ER stress and neurodegenerative diseases Cell Death Differ 13 2006 385 392
103. J.J. Hoozemans, E.S. van Haastert, P. Eikelenboom, R.A. de Vos, J.M. Rozemuller, and W. Scheper Activation of the unfolded protein response in Parkinson's disease Biochem Biophys Res Commun 354 2007 707 711 (Pubitemid 46186242)
104. P. Jiang, M. Gan, A.S. Ebrahim, W.L. Lin, H.L. Melrose, and S.H. Yen Er stress response plays an important role in aggregation of α-synuclein Mol Neurodegener 5 2010 56
105. K.M. Doyle, D. Kennedy, A.M. Gorman, S. Gupta, S.J. Healy, and A. Samali Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders J Cell Mol Med 15 2011 2025 2039
106. I.C. Stefani, D. Wright, K.M. Polizzi, and C. Kontoravdi The role of ER stress-induced apoptosis in neurodegeneration Curr Alzheimer Res 9 2012 373 387
107. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, and J. Kachergus et al. α-synuclein locus triplication causes Parkinson's disease Science 302 2003 841 (Pubitemid 37339619)
108. S.J. Orenstein, S.H. Kuo, I. Tasset, E. Arias, H. Koga, and I. Fernandez-Carasa et al. Interplay of LRRK2 with chaperone-mediated autophagy Nat Neurosci 16 2013 394 406
109. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047 (Pubitemid 27443610)
110. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, and S. Kosel et al. Ala30pro mutation in the gene encoding α-synuclein in Parkinson's disease [letter] Nat Genet 18 1998 106 108
111. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, and I. Ampuero et al. The new mutation, e46k, of α-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 2004 164 173 (Pubitemid 38166992)
112. D. Boassa, M.L. Berlanga, M.A. Yang, M. Terada, J. Hu, and E.A. Bushong et al. Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis J Neurosci 33 2013 2605 2615
113. S.E. Eisbach, and T.F. Outeiro α-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology J Mol Med 91 2013 693 703
114. T.M. Dawson, and V.L. Dawson The role of Parkin in familial and sporadic Parkinson's disease Mov Disord 25 Suppl. 1 2010 S32 S39
115. S. Geisler, K.M. Holmstrom, D. Skujat, F.C. Fiesel, O.C. Rothfuss, and P.J. Kahle et al. Pink1/Parkin-mediated mitophagy is dependent on vdac1 and p62/sqstm1 Nat Cell Biol 12 2010 119 131
116. S. Geisler, K.M. Holmstrom, A. Treis, D. Skujat, S.S. Weber, and F.C. Fiesel et al. The pink1/parkin-mediated mitophagy is compromised by PD-associated mutations Autophagy 6 2010 871 878
117. C.M. Haynes, and D. Ron The mitochondrial UPR - protecting organelle protein homeostasis J Cell Sci 123 2010 3849 3855